Published in Cell Cycle on April 15, 2010
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY) (2011) 1.74
Risk of cancer in diabetes: the effect of metformin. ISRN Endocrinol (2013) 1.04
Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes (2014) 1.01
Overexpression of dilp2 causes nutrient-dependent semi-lethality in Drosophila. Front Physiol (2014) 0.87
Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocr Relat Cancer (2013) 0.84
Diabetes, glucose control, glucose lowering medications, and cancer risk: a 10-year population-based historical cohort. BMC Cancer (2012) 0.80
Ovariectomy is associated with metabolic impairments and enhanced mammary tumor growth in MKR mice. J Endocrinol (2015) 0.76
Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review. Oncol Lett (2016) 0.75
Risk of skin cancer in patients with diabetes mellitus: A nationwide retrospective cohort study in Taiwan. Medicine (Baltimore) (2016) 0.75
Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study. Diabetes Ther (2016) 0.75
Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth. Front Endocrinol (Lausanne) (2017) 0.75
The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2006) 4.93
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med (2004) 2.51
Minireview: IGF, Insulin, and Cancer. Endocrinology (2011) 2.16
Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 2.13
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res (2002) 1.96
The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes (2012) 1.86
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest (2004) 1.82
Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology (2006) 1.71
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer (2012) 1.48
The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev (2014) 1.45
Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology (2006) 1.44
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res (2003) 1.44
The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.40
The link between the metabolic syndrome and cancer. Int J Biol Sci (2011) 1.37
Pancreatic-specific inactivation of IGF-I gene causes enlarged pancreatic islets and significant resistance to diabetes. Diabetes (2004) 1.36
Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res (2009) 1.35
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci (2011) 1.34
Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol (2008) 1.33
Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am (2007) 1.29
Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology (2005) 1.29
Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes (2003) 1.28
Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes (2009) 1.28
PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene (2004) 1.27
Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem (2002) 1.26
Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J (2008) 1.23
Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology (2009) 1.21
Targeted loss of GHR signaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes (2012) 1.18
TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem (2004) 1.17
PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest (2002) 1.16
Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med (2010) 1.16
Growth hormone receptor regulates β cell hyperplasia and glucose-stimulated insulin secretion in obese mice. J Clin Invest (2011) 1.12
Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology (2004) 1.10
Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep (2010) 1.07
Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res (2010) 1.07
Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology (2008) 1.06
Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Endocrinology (2003) 1.04
Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone (2008) 1.03
Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res (2012) 1.01
Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes (2013) 1.01
Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res (2008) 1.01
High-efficient FLPo deleter mice in C57BL/6J background. PLoS One (2009) 1.01
The metabolic syndrome--from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am (2008) 1.00
Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care (2013) 1.00
A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab (2007) 0.99
Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer (2010) 0.98
Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes (2004) 0.98
Role of growth hormone (GH) in liver regeneration. Endocrinology (2004) 0.97
Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers. Curr Drug Targets (2011) 0.97
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Determining mammosphere-forming potential: application of the limiting dilution analysis. J Mammary Gland Biol Neoplasia (2012) 0.97
Microarray analysis and identification of novel molecules involved in insulin-like growth factor-1 receptor signaling and gene expression. Recent Prog Horm Res (2003) 0.96
Intracerebroventricular leptin infusion improves glucose homeostasis in lean type 2 diabetic MKR mice via hepatic vagal and non-vagal mechanisms. PLoS One (2011) 0.95
The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. Vitam Horm (2013) 0.95
Effects of organ-specific loss of insulin-like growth factor-I production on murine hematopoiesis. Biol Blood Marrow Transplant (2004) 0.95
The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocr Pract (2011) 0.95
The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary alphaT3 cells by protein kinase Calpha-mediated negative regulation of Akt. J Biol Chem (2004) 0.93
Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc (2008) 0.93
Upregulation of heme oxygenase-1 gene by turpentine oil-induced localized inflammation: involvement of interleukin-6. Lab Invest (2005) 0.93
Hepatic CCAAT/enhancer binding protein alpha mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice. Mol Endocrinol (2004) 0.92
Effect of case-based training for medical residents on confidence, knowledge, and management of inpatient glycemia. Postgrad Med (2011) 0.91
Clinical relevance of systemic and local IGF-I. Endocr Dev (2005) 0.91
Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus. Clin Cornerstone (2004) 0.90
Insulin and IGFs in obesity-related breast cancer. J Mammary Gland Biol Neoplasia (2013) 0.89
Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med (2015) 0.89
Insulin-like growth factor-i regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology (2008) 0.88
MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am J Physiol Endocrinol Metab (2006) 0.88
The role of insulin receptor signaling in zebrafish embryogenesis. Endocrinology (2008) 0.88
Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes (2013) 0.87
Decreased IGF type 1 receptor signaling in mammary epithelium during pregnancy leads to reduced proliferation, alveolar differentiation, and expression of insulin receptor substrate (IRS)-1 and IRS-2. Endocrinology (2011) 0.86
The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells. J Biol Chem (2003) 0.86
Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model. Endocrinology (2013) 0.86
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract (2015) 0.85
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Int J Cancer (2009) 0.85
Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocr Relat Cancer (2013) 0.84
Impaired muscle regeneration and myoblast differentiation in mice with a muscle-specific KO of IGF-IR. J Cell Physiol (2010) 0.84
Is growth hormone resistance/IGF-1 reduction good for you? Cell Metab (2011) 0.83
Protection against hypoxic-ischemic injury in transgenic mice overexpressing Kir6.2 channel pore in forebrain. Mol Cell Neurosci (2004) 0.83
Insulin-like growth factor-I: compartmentalization within the somatotropic axis? News Physiol Sci (2002) 0.82
Skeletal muscle growth hormone receptor signaling regulates basal, but not fasting-induced, lipid oxidation. PLoS One (2012) 0.82
Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future! Diabetes Care (2015) 0.82
Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Breast Cancer Res (2012) 0.82
Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Am J Physiol Renal Physiol (2014) 0.82
Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care (2014) 0.81
The GH/IGF-1 axis in growth and development: new insights derived from animal models. Adv Pediatr (2010) 0.81
Insulin-like growth factor (IGF)-binding protein-1 is highly induced during acute carbon tetrachloride liver injury and potentiates the IGF-I-stimulated activation of rat hepatic stellate cells. Endocrinology (2004) 0.80
14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation. J Biol Chem (2004) 0.80
Diabetes cure--is the glass half full? N Engl J Med (2006) 0.80
The WT1 Wilms' tumor suppressor gene: a novel target for insulin-like growth factor-I action. Endocrinology (2003) 0.80
Diabetes, glucose control, glucose lowering medications, and cancer risk: a 10-year population-based historical cohort. BMC Cancer (2012) 0.80